BIONEXUS GENE LAB CORP (BGLC) Fundamental Analysis & Valuation

NASDAQ:BGLC • US0906283066

Current stock price

2.1406 USD
-0.18 (-7.72%)
At close:
2.15 USD
+0.01 (+0.44%)
Pre-Market:

This BGLC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BGLC Profitability Analysis

1.1 Basic Checks

  • In the past year BGLC has reported negative net income.
  • BGLC had a negative operating cash flow in the past year.
  • In multiple years BGLC reported negative net income over the last 5 years.
  • In multiple years BGLC reported negative operating cash flow during the last 5 years.
BGLC Yearly Net Income VS EBIT VS OCF VS FCFBGLC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M -2M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.14%, BGLC is doing worse than 91.49% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -33.70%, BGLC is doing worse than 85.11% of the companies in the same industry.
Industry RankSector Rank
ROA -30.14%
ROE -33.7%
ROIC N/A
ROA(3y)-14.17%
ROA(5y)-4.78%
ROE(3y)-17.27%
ROE(5y)-5%
ROIC(3y)N/A
ROIC(5y)N/A
BGLC Yearly ROA, ROE, ROICBGLC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • BGLC's Gross Margin of 14.77% is on the low side compared to the rest of the industry. BGLC is outperformed by 87.23% of its industry peers.
  • In the last couple of years the Gross Margin of BGLC has declined.
  • The Profit Margin and Operating Margin are not available for BGLC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.25%
GM growth 5Y-21.73%
BGLC Yearly Profit, Operating, Gross MarginsBGLC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BGLC Health Analysis

2.1 Basic Checks

  • BGLC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BGLC has been increased compared to 1 year ago.
  • The number of shares outstanding for BGLC has been increased compared to 5 years ago.
  • BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGLC Yearly Shares OutstandingBGLC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BGLC Yearly Total Debt VS Total AssetsBGLC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • An Altman-Z score of 3.77 indicates that BGLC is not in any danger for bankruptcy at the moment.
  • BGLC has a Altman-Z score of 3.77. This is in the better half of the industry: BGLC outperforms 68.09% of its industry peers.
  • BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.77
ROIC/WACCN/A
WACC8.99%
BGLC Yearly LT Debt VS Equity VS FCFBGLC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M 6M 8M

2.3 Liquidity

  • BGLC has a Current Ratio of 8.30. This indicates that BGLC is financially healthy and has no problem in meeting its short term obligations.
  • BGLC's Current ratio of 8.30 is amongst the best of the industry. BGLC outperforms 100.00% of its industry peers.
  • BGLC has a Quick Ratio of 6.81. This indicates that BGLC is financially healthy and has no problem in meeting its short term obligations.
  • BGLC's Quick ratio of 6.81 is amongst the best of the industry. BGLC outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 8.3
Quick Ratio 6.81
BGLC Yearly Current Assets VS Current LiabilitesBGLC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BGLC Growth Analysis

3.1 Past

  • BGLC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -220.64%.
  • BGLC shows a small growth in Revenue. In the last year, the Revenue has grown by 2.21%.
  • The Revenue has been growing by 135.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-220.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.39%
Revenue 1Y (TTM)2.21%
Revenue growth 3Y-10.71%
Revenue growth 5Y135.97%
Sales Q2Q%-3.29%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BGLC Yearly Revenue VS EstimatesBGLC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

Find the best growth stocksShow best growing peers

0

4. BGLC Valuation Analysis

4.1 Price/Earnings Ratio

  • BGLC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGLC Price Earnings VS Forward Price EarningsBGLC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGLC Per share dataBGLC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BGLC Dividend Analysis

5.1 Amount

  • BGLC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BGLC Fundamentals: All Metrics, Ratios and Statistics

BIONEXUS GENE LAB CORP

NASDAQ:BGLC (3/31/2026, 8:21:09 PM)

Premarket: 2.15 +0.01 (+0.44%)

2.1406

-0.18 (-7.72%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners2.12%
Inst Owner Change114.71%
Ins Owners12.39%
Ins Owner Change0%
Market Cap5.05M
Revenue(TTM)9.47M
Net Income(TTM)-2.30M
AnalystsN/A
Price TargetN/A
Short Float %1.52%
Short Ratio0.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.53
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS4.01
BVpS2.89
TBVpS2.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.14%
ROE -33.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.77%
FCFM N/A
ROA(3y)-14.17%
ROA(5y)-4.78%
ROE(3y)-17.27%
ROE(5y)-5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.25%
GM growth 5Y-21.73%
F-Score4
Asset Turnover1.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.41%
Cap/Sales 0.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.3
Quick Ratio 6.81
Altman-Z 3.77
F-Score4
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)150.92%
Cap/Depr(5y)183.89%
Cap/Sales(3y)1.46%
Cap/Sales(5y)1.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-220.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.39%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.21%
Revenue growth 3Y-10.71%
Revenue growth 5Y135.97%
Sales Q2Q%-3.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-145.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-300.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-404.42%
OCF growth 3YN/A
OCF growth 5YN/A

BIONEXUS GENE LAB CORP / BGLC Fundamental Analysis FAQ

What is the fundamental rating for BGLC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGLC.


What is the valuation status of BIONEXUS GENE LAB CORP (BGLC) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONEXUS GENE LAB CORP (BGLC). This can be considered as Overvalued.


Can you provide the profitability details for BIONEXUS GENE LAB CORP?

BIONEXUS GENE LAB CORP (BGLC) has a profitability rating of 1 / 10.


How financially healthy is BIONEXUS GENE LAB CORP?

The financial health rating of BIONEXUS GENE LAB CORP (BGLC) is 8 / 10.